Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Vaqta Market Size Outlook: How Fast Will Revenue Grow Through 2030?
Growth during the historical timeframe is linked to the broadening of routine immunization programs, a higher frequency of hepatitis A outbreaks, a surge in international travel, vaccination campaigns driven by governments, and enhanced standards in vaccine production.
The expansion observed during the forecast period is driven by a heightened emphasis on achieving universal vaccination coverage, greater financial commitments to strengthening public health systems, the broadening of immunization initiatives targeting adults and the elderly, a rising preference for combination vaccine approaches, and increased uptake in developing markets. Key developments shaping this period involve a stronger focus on preventative vaccination efforts, a growing trend toward travel-associated immunizations, an intensified push for adult vaccination rates, the widening of cold-chain logistics for vaccine delivery, and more effective public health education initiatives.
Download A Free Sample Report For Comprehensive Market Insights:
Vaqta Market Growth Momentum: Which Factors Are Influencing Demand?
The anticipated increase in hepatitis A cases is set to drive forward the expansion of the vaqta market. Hepatitis A, a highly contagious liver infection, results from the hepatitis A virus (HAV). This rise in infections stems from various causes like inadequate sanitation and hygiene, community outbreaks, unvaccinated groups, foodborne transmissions, and environmental influences. The vaqta vaccine plays a key role in curbing the spread of the virus, particularly in high-risk settings, by reducing infection rates. For example, in April 2025, the Health Security Agency, a UK-based government body, reported that while hepatitis A virus infections in the UK typically occur at about 400 cases annually, numbers have climbed, exceeding 800 by 2024. Consequently, this uptick in hepatitis A cases is fueling growth in the vaqta market.
Vaqta Market Driver: Growing Prevalence Of Chronic Diseases Fueling Demand For Preventive Vaccination Strategies
The upward trend in chronic disease prevalence is anticipated to accelerate the vaqta market’s growth moving forward. Chronic diseases are enduring conditions that last a year or more, demanding continuous medical care or restricting daily activities. They generally evolve slowly and can be managed, but not cured. Their increasing prevalence is driven by aging demographics, unhealthy lifestyle choices, and enhanced diagnostic capabilities. Vaqta serves a crucial preventive function by safeguarding individuals with chronic conditions from hepatitis A infection. For those suffering from liver-related ailments or weakened immune systems, this vaccine can be vital in averting additional liver harm and controlling overall health risks. As an illustration, in September 2023, the World Health Organization (WHO), a Switzerland-based intergovernmental entity, noted that globally, 41 million deaths occur each year—representing 74% of all fatalities—due to chronic diseases. This tally includes 17.9 million deaths from cardiovascular issues, 9.3 million from cancer, 4.1 million from chronic respiratory diseases, and 2.0 million from diabetes. Thus, the escalating prevalence of chronic diseases is propelling the vaqta market’s expansion.
Vaqta Market Driver: Increasing Healthcare Expenditure Enhancing Access To Preventive Vaccination Programs
The escalation in healthcare spending is expected to boost the vaqta market’s progression going forward. Healthcare expenditure denotes the total financial resources allocated to health services and products over a defined timeframe, usually measured annually. This growth in spending is fueled by aging populations, a surge in chronic illnesses, technological medical progress, and broader healthcare availability. Higher healthcare expenditure improves access to Vaqta by supporting vaccination initiatives and broadening preventive care programs. For instance, in May 2024, the Office for National Statistics (ONS), a UK-based government statistical agency, reported that total healthcare expenditure saw a nominal increase of 5.6% between 2022 and 2023, compared to a 0.9% rise in 2022. Therefore, this rise in healthcare expenditure is driving the expansion of the vaqta market.
Vaqta Market Segment Outlook: Which Categories Are Expanding The Fastest?
The vaqta market covered in this report is segmented –
1) By Indication: Hepatitis A Vaccination, Travel Vaccination, Routine Vaccination
2) By Age Group: Pediatrics, Adults, Elderly
3) By Distribution Channel: Hospital And Clinics, Retail Pharmacies, Specialty Pharmacies
4) By End Use: Hospitals, Clinics, Ambulatory Care, Home Care
Vaqta Market Key Companies And Competitive Benchmarking
Major companies operating in the vaqta market are Merck & Co. Inc.
Access The Complete Vaqta Market Report:
Vaqta Market Geographic Analysis: Where Is Demand Growing The Fastest?
North America was the largest region in the vaqta market in 2025. The regions covered in the vaqta market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model